

# COCHLEAR™ NUCLEUS® IMPLANT RELIABILITY REPORT

Volume 15 | January 2017



*Hear now. And always*



Cochlear®



# OUR MISSION

We help people hear and be heard.

We **empower** people to connect with others and live a full life.

We **transform** the way people understand and treat hearing loss.

We **innovate** and bring to market a range of implantable hearing solutions that deliver a lifetime of hearing outcomes.

Cochlear's implants are the most reliable<sup>1</sup> in the industry\*. That's one reason why more people around the world choose Cochlear than any other cochlear implant brand.

\* Latest generation of cochlear implants commercially available as at 30 January 2017

# WHY RELIABILITY MATTERS

High implant reliability means greater patient satisfaction and less risk of additional surgery. When considering a cochlear implant, it's important that you have access to the latest data on short- and long-term reliability, including success and failure rates for both adults and children.

# ABOUT RELIABILITY REPORTING

The global standards for cochlear implant reliability reporting are based on the *International Standard ISO 5841-2*<sup>2,3</sup>, the reporting principles outlined in the *European consensus statement on cochlear implant failures and explantations*<sup>4</sup>, and expert recommendations from the *International classification of reliability for implanted cochlear implant receiver stimulators*.<sup>5</sup>

This report complies with these standards.

---

COCHLEAR'S IMPLANTS ARE THE  
**MOST RELIABLE**<sup>1</sup>  
IN THE INDUSTRY\*

---

\* Latest generation of cochlear implants commercially available as at 30 January 2017

# HOW TO READ THIS REPORT

## What is Cumulative Survival Percentage (CSP)?

The cumulative percentage of functioning implants over time, which indicates the reliability of the device within a given time period.

The reliability calculations used in this report are in accordance with the International Standard ISO 5841-2.<sup>2,3</sup> They are probability calculations, which use a modified Kaplan-Meier estimator. This data estimates the probability of survival within a period of time and is represented as Cumulative Survival Percentage (CSP).

## What data is in this report?

The data in this report covers the entire life of implant models and registered implants\* worldwide.

MORE PEOPLE CHOOSE COCHLEAR THAN ANY OTHER IMPLANT BRAND

OVER 300,000 REGISTERED COCHLEAR NUCLEUS IMPLANTS WORLDWIDE


Number of registered implants - 30 January 2017

DEVICE	ADULTS	CHILDREN	COMBINED
Profile	16,596	12,277	28,873
CI24E	73,254	94,600	167,854
CI500	15,407	14,387	29,794
CI24R	18,694	34,657	53,351
CI24H (All)	7866	11,827	19,723
CI224	5,958	8,229	14,181

Cumulative Survival Percentage (CSP) data for combined adults and children

YEARS	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	
CI500	99.2	98.7	98.2	97.8	97.3	96.7	96.2	95.7	95.2	94.7	94.2	93.7	93.2	92.7	92.2	91.7	91.2	90.7	90.2	89.7	89.2	88.7	88.2	87.7	87.2	86.7	86.2	85.7	85.2	84.7	84.2
CI24E	99.4	98.9	98.4	97.9	97.4	96.9	96.4	95.9	95.4	94.9	94.4	93.9	93.4	92.9	92.4	91.9	91.4	90.9	90.4	89.9	89.4	88.9	88.4	87.9	87.4	86.9	86.4	85.9	85.4	84.9	84.4
CI24R	99.3	98.8	98.3	97.8	97.3	96.8	96.3	95.8	95.3	94.8	94.3	93.8	93.3	92.8	92.3	91.8	91.3	90.8	90.3	89.8	89.3	88.8	88.3	87.8	87.3	86.8	86.3	85.8	85.3	84.8	84.3
CI24H	99.1	98.6	98.1	97.6	97.1	96.6	96.1	95.6	95.1	94.6	94.1	93.6	93.1	92.6	92.1	91.6	91.1	90.6	90.1	89.6	89.1	88.6	88.1	87.6	87.1	86.6	86.1	85.6	85.1	84.6	84.1
CI224	98.9	98.4	97.9	97.4	96.9	96.4	95.9	95.4	94.9	94.4	93.9	93.4	92.9	92.4	91.9	91.4	90.9	90.4	89.9	89.4	88.9	88.4	87.9	87.4	86.9	86.4	85.9	85.4	84.9	84.4	83.9
Profile	99.5	99.0	98.5	98.0	97.5	97.0	96.5	96.0	95.5	95.0	94.5	94.0	93.5	93.0	92.5	92.0	91.5	91.0	90.5	90.0	89.5	89.0	88.5	88.0	87.5	87.0	86.5	86.0	85.5	85.0	84.5

Nucleus Implant Reliability



## What is combined data?

This is the cumulative survival percentage of both adults and children populations combined.

## How are results shown?

Results for adults and children are shown separately with 95% confidence intervals (I) as required by the consensus statement.<sup>4</sup>

\* An implant is registered with Cochlear when clinic/hospital submits the registration of the implanted device. Implant registrations often lag behind surgery dates.

# COMPLIANCE WITH INTERNATIONAL REPORTING STANDARDS

In 2005, the major European cochlear implant centres, global regulatory authorities and device manufacturers developed the *European consensus statement on cochlear implant failures and explantations*.<sup>4</sup> The consensus statement outlines how device failures and reliability should be reported, and the seven principles of best practice reporting.

## CONSENSUS STATEMENT PRINCIPLES

All device failures must be reported to the competent authority and must be included in the calculation of the Cumulative Survival Rate (CSR\*). Reporting of the CSR should be in accordance with International Standard ISO 5841-2:2000.<sup>2</sup>

Manufacturer's reports of device failure should indicate the sources of data and the sample size. There must be no exclusions. The time period over which the data was collected should be specified.

Reports of CSR should give complete historical data of a given device, describing any technical modifications (which can be integrated into historical data by starting at time 0).

The complete data set of the 'mother'<sup>\*\*\*</sup> product should always be supplied when presenting data on subsequent device modifications.

A new device can be attributed when there has been a change in either the case and/or the electrodes and/or the electronics and has been labelled by its own CE mark.

Cumulative Survival Rate should be split into data for adults and for children and 95% confidence intervals (80% or 90% if the population is below 1,000 units) should be provided.

Device survival time starts to count with closure of the wound intraoperatively.

\* CSR is identical to Cumulative Survival Percentage (CSP).

\*\* 'Mother' data refers to all data collected for a particular model of implant including all modifications to that model.

COCHLEAR REPORTING PRACTICE	COCHLEAR COMPLIANCE	MED-EL COMPLIANCE <sup>6</sup>	ADVANCED BIONICS COMPLIANCE <sup>7</sup>
<p>All device failures are reported to the competent authority.</p> <p>Cochlear uses the applicable definitions, categorisation scheme and calculation procedures of both ISO 5841-2:2000<sup>2</sup> and ISO 5841-2:2014.<sup>3</sup></p> <p>All device failure modes are included, including failures due to external impact.</p>	✓	<p>✓</p> <p>Compliance with ISO 5841-2:2014<sup>3</sup> not explicitly stated.<sup>6</sup></p>	✓
<p>The source of data is Cochlear's global complaints handling database.</p> <p>Sample size and time period are specified with each report.</p>	✓	<p>✗</p> <p>Sample size not included.</p>	✓
<p>All models and all versions of each model are included in reports.</p> <p>Descriptions of any significant technical modifications are given.</p>	✓	<p>✗</p> <p>COMBI 40+ no longer reported. PULSAR no longer reported.</p>	✓
<p>Reports aggregate the reliability of all devices (pre- and post- modification). If the post-modification is significantly different, post-modification is reported separately from the aggregate of all devices.</p>	✓	<p>✗</p> <p>COMBI 40+ no longer reported. PULSAR no longer reported.</p>	✓
<p>A new device is attributed when there has been a change in either the case and/or the electrodes and/or the electronics and has been labelled by its own CE mark. Market practice is that all cochlear implants are labeled by one CE mark per authority.</p>	✓	<p>?</p> <p>Not explicitly stated.</p>	<p>?</p> <p>Not explicitly stated.</p>
<p>Reports show separate data for adults and children.</p> <p>This Nucleus<sup>®</sup> Reliability Report contains reliability data with 95% confidence intervals, in compliance with the consensus statement.<sup>4</sup></p>	✓	<p>✗</p> <p>No split data on adults and children. Confidence intervals not included.</p>	✓
<p>All failures are counted that occur any time after wound closure.</p>	✓	<p>?</p> <p>Not explicitly stated.</p>	✓

# MORE PEOPLE CHOOSE COCHLEAR THAN ANY OTHER IMPLANT BRAND

OVER **300,000**  
REGISTERED COCHLEAR  
NUCLEUS IMPLANTS  
WORLDWIDE

## Number of registered implants - 30 January 2017


DEVICE	ADULTS	CHILDREN	COMBINED
Profile	16,586	12,277	28,863
CI24RE	72,594	94,600	167,194
CI500	15,407	14,387	29,794
CI24R	18,694	34,657	53,351
CI24M (All)	7,866	11,857	19,723
CI22M	9,958	8,223	18,181

## Cumulative Survival Percentage (CSP) data for combined adults and children

YEARS	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	
CI22M	99.2	98.7	98.2	97.8	97.5	97.2	96.9	96.7	96.5	96.2	96	95.7	95.5	95.2	95.0	94.8	94.7	94.5	94.2	93.9	93.6	93.4	93.2	92.8	92.5	92.3	92.2	92.1	91.8	
CI24M (All)	99.4	98.9	98.4	98.2	98.0	97.9	97.7	97.6	97.5	97.3	97.2	97.1	97.1	97.0	97.0	96.9	96.8	96.8	96.8											
CI24R	99.7	99.5	99.3	99.1	98.9	98.8	98.6	98.5	98.4	98.3	98.2	98.1	98.0	97.9	97.8	97.6	97.5													
CI24RE	99.8	99.7	99.6	99.5	99.5	99.4	99.3	99.3	99.2	99.1	99.0	99.0																		
CI500	96.2	93.9	92.7	92.0	91.4	90.9	90.8	90.8																						
Profile	99.97	99.94	99.94																											



## Nucleus Implant Reliability



REGISTERED IMPLANT DATA COMBINED FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

\* Voluntarily recalled in September 2011.  
 Confidence intervals smaller than 0.1% may not be clearly visible in the graphs.



# CURRENTLY AVAILABLE IMPLANTS

# NUCLEUS PROFILE SERIES IMPLANT



Number of registered Profile Series implants - 30 January 2017

ADULTS	CHILDREN	COMBINED
16,586	12,277	28,863

At only 3.9 mm, the thin implant body of the Profile Series is the most discreet choice for all patients.

Commercially released in 2014, the Profile Series sets a new standard in implant reliability with a 99.94% combined Cumulative Survival Percentage within three years.

## Profile Series Cumulative Survival Percentage

YEAR	1	2	3
Adults	99.98	99.94	99.94
Children	99.94	99.94	99.94
Combined	99.97	99.94	99.94



## Profile Series Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

Confidence intervals smaller than 0.1% may not be clearly visible in the graphs.

# NUCLEUS CI24RE SERIES IMPLANT



Number of registered CI24RE Series implants - 30 January 2017

ADULTS	CHILDREN	COMBINED
72,594	94,600	167,194

The CI24RE Series is the world's most widely used cochlear implant.


Released in 2005, it has a record of 99.00% combined Cumulative Survival Percentage within 12 years.

## CI24RE Series Cumulative Survival Percentage

YEARS	1	2	3	4	5	6	7	8	9	10	11	12
Adults	99.9	99.8	99.7	99.7	99.6	99.5	99.5	99.5	99.4	99.4	99.4	99.4
Children	99.8	99.7	99.5	99.4	99.3	99.2	99.2	99.1	99.1	98.8	98.7	98.6
Combined	99.8	99.7	99.6	99.5	99.5	99.4	99.3	99.3	99.2	99.1	99.0	99.0

CI24RE:  
OVER 167,000 DEVICES  
IMPLANTED  
99.00% CSP WITHIN  
12 YEARS

## CI24RE Series Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

Confidence intervals smaller than 0.1% may not be clearly visible in the graphs.





# PREVIOUSLY AVAILABLE IMPLANTS

# NUCLEUS CI500 SERIES IMPLANT



## Number of registered CI500 Series implants - 30 January 2017

ADULTS	CHILDREN	COMBINED
15,407	14,387	29,794


Released in 2009, the CI500 Series has a combined Cumulative Survival Percentage of 90.8% within eight years.

The CI500 Series was voluntarily recalled in September 2011.

## CI500 Series Cumulative Survival Percentage

YEARS	1	2	3	4	5	6	7	8
Adults	95.9	93.9	92.8	92.2	91.7	91.4	91.3	91.3
Children	96.6	94.0	92.7	91.7	91.0	90.4	90.2	90.2
Combined	96.2	93.9	92.7	92.0	91.4	90.9	90.8	90.8

# CI500 Series Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

# NUCLEUS CI24R IMPLANT



## Number of registered CI24R implants - 30 January 2017


ADULTS	CHILDREN	COMBINED
18,694	34,657	53,351

The CI24R was released in 2000 with perimodiolar (Contour Advance®) and straight electrodes. Within 17 years, the CI24R implant has a combined Cumulative Survival Percentage of 97.5%.

## CI24R Cumulative Survival Percentage

YEARS	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
<b>Adults</b>	99.8	99.6	99.5	99.4	99.3	99.1	99.0	98.9	98.8	98.8	98.7	98.6	98.6	98.5	98.5	98.3	98.3
<b>Children</b>	99.7	99.4	99.1	98.9	98.8	98.6	98.4	98.2	98.1	98.0	97.9	97.8	97.6	97.5	97.4	97.2	97.0
<b>Combined</b>	99.7	99.5	99.3	99.1	98.9	98.8	98.6	98.5	98.4	98.3	98.2	98.1	98.0	97.9	97.8	97.6	97.5

# CI24R Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

# NUCLEUS CI24M IMPLANT



## Number of registered CI24M implants - 30 January 2017

	ADULTS	CHILDREN	COMBINED
ALL	7,866	11,857	19,723
POST**	6,156	9,339	15,495

Released in 1997, the CI24M implant was the world's first cochlear implant with a removable magnet for MRI safety.

Within 20 years, the CI24M implant has a combined Cumulative Survival Percentage of 96.8%.


## CI24M Cumulative Survival Percentage

YEARS	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Adults (All)	99.8	99.7	99.7	99.6	99.5	99.5	99.4	99.4	99.3	99.2	99.1	99.0	99.0	98.9	98.9	98.8	98.7	98.7	98.7	98.7
Children (All)	99.2	98.3	97.6	97.3	97.0	96.8	96.6	96.4	96.3	96.1	96.0	95.9	95.8	95.8	95.7	95.7	95.6	95.5	95.5	95.5
Combined (All)	99.4	98.9	98.4	98.2	98.0	97.9	97.7	97.6	97.5	97.3	97.2	97.1	97.1	97.0	97.0	96.9	96.8	96.8	96.8	96.8
Adults (Post)	99.8	99.7	99.7	99.6	99.5	99.5	99.4	99.3	99.2	99.2	99.1	99.0	99.0	98.9	98.9	98.8	98.8	98.8	#	#
Children (Post)	99.4	98.6	98.0	97.8	97.5	97.3	97.2	97.0	96.8	96.7	96.5	96.5	96.4	96.3	96.3	96.2	96.2	96.1	96.1	#
Combined (Post)	99.5	99.1	98.7	98.5	98.3	98.2	98.0	97.9	97.8	97.7	97.5	97.5	97.4	97.4	97.3	97.2	97.2	97.2	97.2	#

\*\* 'Post' refers to the addition of a structural support component to improve impact strength.

# Individual populations are less than the minimum required for a valid calculation.<sup>3</sup>

## CI24M Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

# NUCLEUS CI22M IMPLANT



## Number of registered CI22M implants - 30 January 2017

ADULTS	CHILDREN	COMBINED
9,958	8,223	18,181

Released in 1985, the CI22M implant was the first commercially available multi-channel cochlear implant in the world.

Within 29 years, the CI22M implant has a combined Cumulative Survival Percentage of 91.8%.

## CI22M Cumulative Survival Percentage

YEARS	1	2	3	4	5	6	7	8	9	10	11	12	13	14
<b>Adults</b>	99.3	98.9	98.7	98.5	98.4	98.2	98.1	98.0	97.9	97.6	97.5	97.4	97.2	96.9
<b>Children</b>	99.2	98.3	97.6	96.9	96.5	96.0	95.5	95.2	94.8	94.5	94.2	93.8	93.5	93.3
<b>Combined</b>	99.2	98.7	98.2	97.8	97.5	97.2	96.9	96.7	96.5	96.2	96.0	95.7	95.5	95.2


  

15	16	17	18	19	20	21	22	23	24	25	26	27	28	29
96.7	96.6	96.4	96.2	96.0	95.7	95.5	95.3	95.1	94.7	94.3	94.2	94.0	93.9	93.7
92.9	92.7	92.6	92.4	92.0	91.8	91.4	91.2	91.0	90.7	90.4	90.0	90.0	90.0	#
95.0	94.8	94.7	94.5	94.2	93.9	93.6	93.4	93.2	92.8	92.5	92.3	92.2	92.1	91.8

# Individual populations are less than the minimum required for a valid calculation.<sup>3</sup>



## CI22M Reliability



REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 30 JANUARY 2017

# APPENDIX

## GRAPHICAL REPRESENTATION

Each graph represents a type of device based on the receiver/stimulator portion.

RECEIVER/ STIMULATOR	IMPLANTS*
Profile Series	Cochlear Nucleus Profile with Contour Advance Electrode (CI512) Cochlear Nucleus Profile with Slim Straight Electrode (CI522) Cochlear Nucleus Profile with Slim Modiolar Electrode (CI532) Cochlear Nucleus Profile Auditory Brainstem Implant (ABI541)
CI24RE Series	Nucleus Freedom® with Contour Advance Electrode Nucleus Freedom with Straight Electrode Cochlear Nucleus CI422 Cochlear Implant Cochlear Hybrid™ L24 Cochlear Implant
CI500 Series	Cochlear Nucleus CI512 Cochlear Implant Cochlear Nucleus CI513 Cochlear Implant Cochlear Nucleus CI551 Double Array Cochlear Implant Cochlear Nucleus ABI541 Auditory Brainstem Implant
CI24R	Nucleus 24 with Contour Advance Electrode Nucleus 24 with Contour® Electrode Nucleus 24k with Straight Electrode
CI24M	Nucleus 24 with Straight Electrode Nucleus 24 with Double Array Nucleus 24 Auditory Brainstem Implant [ABI]
CI22M	Nucleus 22

\* Implant availability varies by market.

## REFERENCES

1. Cochlear Limited, 454378 ISS10 MAR17. Comparison of reliability of cochlear implants commercially available (as at 30 January 2017, March 2017). Data on file. [Sponsored by Cochlear]
2. International standard ISO 5841-2. Implants for surgery — Cardiac Pacemakers — part 2: Reporting of clinical performance of populations of pulse generators or leads. Geneva (Switzerland): International Organization for Standardization. 2000.
3. International standard ISO 5841-2. Implants for surgery — Cardiac Pacemakers — part 2: Reporting of clinical performance of populations of pulse generators or leads. Geneva (Switzerland): International Organization for Standardization. 2014.
4. European consensus statement on cochlear implant failures and explantations. *Otol Neurotol*. 2005 Nov;26(6):1097-9.
5. Battmer RD, Backous DD, Balkany TJ, Briggs RJ, Gantz BJ, van Hasselt A, et al. International classification of reliability for implanted cochlear implant receiver stimulators. *Otol Neurotol*. 2010 Oct;31(8):1190-3.
6. Reliability You Can Count On [Internet]. MED-EL. January 2016 [cited 10 February 2017]. Available from: <http://www.medel.com/reliability-reporting/>
7. 2016 Cochlear Implant Reliability Report [Internet]. 028-M797-02 RevB ©2016 Advanced Bionics AG and affiliates. All rights reserved. [cited 10 January 2017]; Available from: [http://www.advancedbionics.com/content/dam/ab/Global/en\\_ce/documents/candidate/2016-cochlear-implant-reliability-report.pdf](http://www.advancedbionics.com/content/dam/ab/Global/en_ce/documents/candidate/2016-cochlear-implant-reliability-report.pdf)



# Hear now. And always

As the global leader in implantable hearing solutions, Cochlear is dedicated to bringing the gift of sound to people with moderate to profound hearing loss. We have helped over 450,000 people of all ages live full and active lives by reconnecting them with family, friends and community.

We aim to give our recipients the best lifelong hearing experience and access to innovative future technologies. For our professional partners, we offer the industry's largest clinical, research and support networks.

That's why more people choose Cochlear than any other hearing implant company.



**Cochlear Ltd** (ABN 96 002 618 073) 1 University Avenue, Macquarie University, NSW 2109, Australia Tel: +61 2 9428 6555 Fax: +61 2 9428 6352

[www.cochlear.com](http://www.cochlear.com)

Please seek advice from your medical practitioner or health professional about treatments for hearing loss. They will be able to advise you on a suitable solution for your hearing loss condition. All products should be used only as directed by your medical practitioner or health professional.

Not all products are available in all countries. Please contact your local Cochlear representative.

ACE, Advance Off-Stylet, AOS, AutoNRT, Autosensitivity, Beam, Button, Carina, Cochlear, Cochlear SoftWear, コクレア, Codacs, Contour, Contour Advance, Custom Sound, ESprit, Freedom, Hear now. And always, Hugfit, Hybrid, inHear, Invisible Hearing, Kanso, MET, MicroDrive, MP3000, myCochlear, mySmartSound, NRT, Nucleus, 科利耳, Off-Stylet, SmartSound, Softip, SPrint, True Wireless, the elliptical logo and Whisper are either trademarks or registered trademarks of Cochlear Limited. Ardiium, Baha, Baha SoftWear, BCDrive, DermaLock, EveryWear, Vistafix and WindShield are either trademarks or registered trademarks of Cochlear Bone Anchored Solutions AB.

© Cochlear Limited 2017.  
D1175804 ISS1 MAR17